Skip to main content
letter
. 2023 Mar 24;7(4):e857. doi: 10.1097/HS9.0000000000000857

Figure 1.

Figure 1.

Survival of newly diagnosed multiple myeloma (NDMM) patients according to the R2-ISS. (A, B) PFS (A; median: 48.7, 37.5, 24.3, and 16.3 mo for R2-ISS I–IV, respectively) and OS (B; median: 139.0, 82.2, 51.8, 29.5 mo for R2-ISS I–IV, respectively) of all patients (n = 1005). (C) OS of patients with age >65 y (n = 314; median: 125.3, not reached [NR], 43.3, and 30.5 mo for R2-ISS I–IV, respectively). (D) OS of patients who received either proteasome inhibitor (PI)- or immunomodulatory drug (IMiD)-based induction (n = 688; median: 139.0, 82.8, 49.7, and 27.1 mo for R2-ISS I-IV, respectively). (E, F) PFS (E; median: 39.6, 25.3, and 21.3 mo for R2-ISS II–IV, respectively) and OS (F; median: 82.2, 53.8, and 40.5 mo for R2-ISS II–IV, respectively) of R-ISS II patients (n = 624). OS = overall survival; PFS = progression-free survival; R2-ISS = second revision of international staging system.